KN046 Combined With Ningatinib in the Treatment of Advanced Hepatocellular Carcinoma

NCT04601610 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

TERMINATED

Status

6

Enrollment

INDUSTRY

Sponsor class

Stopped The sponsor's development strategy adjustment resolution is terminated

Conditions

Advanced HCC

Interventions

DRUG: KN046 （PD-L1/CTLA4 BsAb）
DRUG: Ningetinib Tosylate（multi-target TKI）

Sponsor

Jiangsu Alphamab Biopharmaceuticals Co., Ltd

Collaborators

[object Object]